ALNY

Alnylam and Genzyme Form Alliance to Develop and Commercialize RNAi Therapeutics in Asia

[at noodls] – – Genzyme to Advance ALN-TTR02 and ALN-TTRsc Programs as Breakthrough Therapies for Patients with ATTR in Japan and in the Broader Asian Market – – Alnylam to Receive $22.5 Million in Upfront Payment in … moreView todays social media effects on ALNYView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Early Hope for Huntington’s Disease and Further Validation of Sangamo Platform

[ACN Newswire] – By David SobekHuntington’s disease is an inherited neurodegenerative disorder that leads to the progressive degeneration of nerve cells in the brain. The disease is genetic in nature and is caused by a … moreView todays social media effects on ALNYView the latest stocks trending across Twitter. Click to view dashboard […]

Regulus Announces Pricing of Initial Public Offering

[at noodls] – LA JOLLA, CA, October 4, 2012 – Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today … moreView todays social media effects on ALNYView the latest stocks trending across Twitter. Click to view dashboard […]